comprehensive -WSS

comprehensive

author：explore 2025-09-03 05:27:30 - browse：67582

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Empower primary care with adequate payments and technology

focus

WSS

Crowdfunding for medical bills sidesteps core problem, author says

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Woman returns to dialysis after doctors remove transplanted pig kidney

ASCO: Palliative care found as helpful given virtually as in person

See how much Covid

focus

comprehensive

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Deliver public health messages at the right time

Activists slam private health insurers over coverage restrictions

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Guidelines to prevent youth baseball injuries need more muscle

Ionis drug prevents swelling attacks due to hereditary angioedema

Malaria cases in Florida and Texas: Here’s what you need to know

Let's speed up science by embracing open access publishing

Duchenne breakthrough therapy leaves behind pioneering families

Welsh Carson private equity firm escapes from FTC antitrust case

focus

Intellia reports positive results for its CRISPR

ASCO: Palliative care found as helpful given virtually as in person

Letters to First Opinion on caregivers, digital health, and more

FDA's Pazdur wants cancer trials to range beyond China alone

Lawmakers grill UnitedHealth CEO on Change cyberattack

Cord blood banking comes at a high cost to babies

focus

hotspot

Wikipedia

knowledge